- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 115 Years · Male only
- Enrollment
- 17,111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 862
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Cancer
- Interventions
- ixabepilone
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 28
- States / cities
- Los Angeles, California • Sacramento, California • Atlanta, Georgia + 19 more
- Conditions
- Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Male Urogenital Diseases, Prostatic Diseases, Urogenital Diseases, Male, Genital Diseases, Male, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Genital Neoplasms, Male
- Interventions
- 18F-Fluciclovine PET/CT Scan
- Drug
- Lead sponsor
- VA Greater Los Angeles Healthcare System
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer
- Interventions
- BPX-601
- Genetic
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Hackensack, New Jersey • Portland, Oregon
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- [Lu-177]-PNT2002, Abiraterone, Enzalutamide
- Drug
- Lead sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Los Angeles, California • Newport Beach, California + 24 more
- Conditions
- Breast Cancer, Prostate Cancer
- Interventions
- HER2 FPBMC
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Prostate Cancer
- Interventions
- Lenalidomide, Paclitaxel
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer
- Interventions
- Pembrolizumab, Chemotherapy
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Castration Resistant Prostate Cancer
- Interventions
- OGX-427, Prednisone
- Drug
- Lead sponsor
- British Columbia Cancer Agency
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer Recurrent
- Interventions
- Low protein diet, Control protein diet
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Solid Tumor, Adult
- Interventions
- SM08502
- Drug
- Lead sponsor
- Biosplice Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 14 more
- Conditions
- Prostate Cancer
- Interventions
- Abiraterone Acetate, Prednisone, Sunitinib, Dasatinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- therapeutic autologous lymphocytes
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab, Enzalutamide, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 28
- States / cities
- Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- human retinal progenitor cells, Mock injection
- Biological · Other
- Lead sponsor
- jCyte, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Irvine, California • Los Angeles, California • Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- Selinexor
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
- Interventions
- CT (Computed Tomography), Gallium Ga 68-DOTATATE, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
- Interventions
- cabozantinib, mitoxantrone, prednisone
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 49
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 42 more
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
- Interventions
- JANX007, Darolutamide
- Biological · Drug
- Lead sponsor
- Janux Therapeutics
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
- Conditions
- Prostate Cancer
- Interventions
- ARN-509 (Phase 1), ARN-509 (Phase 2)
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2025
- U.S. locations
- 15
- States / cities
- San Diego, California • San Francisco, California • Atlanta, Georgia + 12 more
- Conditions
- Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Interventions
- Cixutumumab, Diagnostic Laboratory Biomarker Analysis, Temsirolimus
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • New York, New York + 1 more
- Conditions
- Prostate Cancer
- Interventions
- Ipilimumab, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 988 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 44
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 39 more
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Small Cell Carcinoma
- Interventions
- Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- PLX3397
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York